The EU's drugs regulator has said that blood clots should be listed as a "very rare" side effect of the Johnson & Johnson Covid-19 vaccine.

The European Medicines Agency said in a statement that it had found a "possible link" between the jab and clots.

But it added that the benefits of the Covid-19 vaccine outweighed the risks.

Out of more than seven million people who have received the jab in the US, eight people developed rare blood clots, including one person who died.

https://www.bbc.com/news/world-europe-56820970

Earlier this month, the EMA made the same recommendation for the Covid-19 vaccine produced by Oxford-AstraZeneca.

That recommendation, made on 7 April, came after 86 out of 25 million Europeans administered with the jab developed the unusual blood clots.

The UK then stopped administering the AstraZeneca vaccine to people under 30 years old.

Last week, the EU, the US and South Africa paused the rollout of the Johnson & Johnson jab in response to the reports of rare blood clotting.

In a statement released on Tuesday, the EMA recommended that blood clots should be listed as a "very rare" side effect of the Johnson & Johnson vaccine (also known as the Janssen vaccine).

The cases of clotting in the US "occurred in people under 60 years of age within three weeks after vaccination, the majority in women", the regulator said.